You are here

Resources to help you transition to teaching online

Instructors: To support your transition to online learning, please see our resources and tools page whether you are teaching in the UK, or teaching outside of the UK.

Inspection copy update April 2020: Due to the current restrictions in place in response to COVID-19, our inspection copy policy has changed. Please refer to our updated inspection copy policy for full details. If you have recently placed an inspection copy order with us, we will be in touch to advise of any changes.

ICRP Publication 94

ICRP Publication 94
Release of Patients after Therapy with Unsealed Radionuclides

Other Titles in:

May 2005 | 84 pages | SAGE Publications Ltd
After some therapeutic nuclear medicine procedures with unsealed radionuclides, precautions may be needed to limit doses to other people, but this is rarely the case after diagnostic procedures. Iodine-131 results in the largest dose to medical staff, the public, caregivers, and relatives. Other radionuclides used in therapy are usually simple beta emitters (e.g. phosphorus-32, strontium-89, and yttrium-90) that pose much less risk. Dose limits apply to exposure of the public and medical staff from patients. Previously, the ICRP has recommended that a source-related dose constraint for optimisation of a few mSv/episode applies to relatives, visitors, and caregivers at home, rather than a dose limit. The present report recommends that young children and infants, as well as visitors not engaged in direct care or comforting, should be treated as members of the public (i.e. be subject to the public dose limit). 

The modes of exposure to other people are: external exposure; internal exposure due to contamination; and environmental pathways. Dose to adults from patients is mainly due to external exposure. Contamination of infants and children with saliva from a patient could result in significant doses to the child’s thyroid. It is important to avoid contamination of children and pregnant women. After radioiodine therapy, mothers must cease breastfeeding immediately. Many types of therapy with unsealed radionuclides are contraindicated in pregnant females. Women should not become pregnant for some time after radioisotope therapy. Technetium-99m dominates discharges to the environment from excreta of nuclear medicine patients, but its short half-life limits its importance. The second largest discharges, iodine-131, can be detected in the environment after medical uses but with no measurable environmental impact. Storing patients' urine after therapy appears to have minimal benefit.

Preview this book

For instructors

To inquire about the availability of this title for review (print and/or digital), please contact your local sales representative or call (800) 818-7243.

Select a Purchasing Option

ISBN: 9780080445601